Cubist Begins Patient Enrolment in Phase III CB-5945 OIC ascent Programme
In its Phase III CB-5945 ascent study for the treatment of OIC Pipeline Drugs Market, Cubist Pharmaceuticals has begun enrolling patients.
One of four registrational studies on patients with chronic non-cancer pain is the multicentre, long-term safety study.
The placebo-controlled, double-blind, randomised (1:1) study will enroll 1,400 eligible US and Canadian patients to evaluate CB-5945 (0.25...
0 Comments
0 Shares